IQV Stock Analysis: IQVIA Holdings | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 44.334m USD | 12M Return: 28.9% | US46266C1053 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 363M
EPS Trend: 97.5%
Qual. Beats: 0
Rev. Trend: 97.0%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights, and healthcare intelligence for the life sciences and healthcare industries, operating across the Americas, Europe, Africa, and Asia-Pacific. The company is organized into three segments: Technology & Analytics Solutions, which delivers cloud-based applications, real-world evidence generation, and consulting services; Research & Development Solutions, which offers clinical trial management, central laboratory, genomic, and bioanalytical services; and Contract Sales & Medical Solutions, which provides healthcare provider and patient engagement along with scientific and medical services. Its customers include pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. IQVIA maintains a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development and is headquartered in Durham, North Carolina, after rebranding from Quintiles IMS Holdings, Inc. in November 2017.
IQVIA operates in the contract research organization (CRO) and health data analytics space, a segment of the broader life sciences tools and services industry that supports drug development, commercialization, and post-market evidence generation for healthcare clients.
- Biotech funding rebound lifts clinical trial bookings and R&D revenue
- Real-world evidence demand expands Technology and Analytics margins
- High debt load pressures free cash flow as interest rates stay elevated
| Net Income: 1.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.37 > 1.0 |
| NWC/Revenue: -7.66% < 20% (prev -15.90%; Δ 8.24% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.74b > Net Income 1.39b |
| Net Debt (14.1b) to EBITDA (3.60b): 3.93 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (167.0m) vs 12m ago -2.74% < -2% |
| Gross Margin: 26.46% > 18% (prev 33.78%; Δ -7.32% > 0.5%) |
| Asset Turnover: 58.48% > 50% (prev 55.36%; Δ 3.12% > 0%) |
| Interest Coverage Ratio: 3.03 > 6 (EBIT TTM 2.38b / Interest Expense TTM 785.0m) |
| A: -0.04 (Total Current Assets 6.45b - Total Current Liabilities 7.78b) / Total Assets 30.5b |
| B: 0.27 (Retained Earnings 8.30b / Total Assets 30.5b) |
| C: 0.08 (EBIT TTM 2.38b / Avg Total Assets 29.6b) |
| D: 0.28 (Book Value of Equity 6.66b / Total Liabilities 23.7b) |
| Altman-Z'' = 1.44 = BB |
| DSRI: 0.92 (Receivables 3.33b/3.31b, Revenue 17.3b/15.9b) |
| GMI: 1.28 (GM 33.78% / 26.46%) |
| AQI: 1.00 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.09 (Revenue 17.3b / 15.9b) |
| TATA: -0.04 (NI 1.39b - CFO 2.74b) / TA 30.5b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of November 08, 2026, the stock is trading at USD 271.83 with a total of 1,398,188 shares traded. Over the past week, the price has changed by +1.68%, over one month by +4.56%, over three months by +16.95% and over the past year by +28.91%.
Current recommended Stop Loss: 260.70 (which is 4.1% or 1.2 ATR below the current price).
IQVIA Holdings has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy IQV.
- StrongBuy: 16
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 311.9 | 14.7% |
P/E Trailing = 32.7275
P/E Forward = 18.2815
P/S = 2.5611
P/B = 6.5544
P/EG = 0.9769
Revenue TTM = 17.3b USD
EBIT TTM = 2.38b USD
EBITDA TTM = 3.60b USD
Long Term Debt = 14.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.24b USD (from shortTermDebt, last quarter)
Debt = 16.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 247.0m
Net Debt = 14.1b USD (calculated: Debt 16.6b - CCE 2.42b)
Enterprise Value = 58.5b USD (44.3b + Debt 16.6b - CCE 2.42b)
Interest Coverage Ratio = 3.03 (Ebit TTM 2.38b / Interest Expense TTM 785.0m)
EV/FCF = 28.13x (Enterprise Value 58.5b / FCF TTM 2.08b)
FCF Yield = 3.56% (FCF TTM 2.08b / Enterprise Value 58.5b)
FCF Margin = 12.01% (FCF TTM 2.08b / Revenue TTM 17.3b)
Net Margin = 8.05% (Net Income TTM 1.39b / Revenue TTM 17.3b)
Gross Margin = 26.46% ((Revenue TTM 17.3b - Cost of Revenue TTM 12.7b) / Revenue TTM)
Gross Margin QoQ = 33.83% (prev 32.85%)
Tobins Q-Ratio = 1.92 (Enterprise Value 58.5b / Total Assets 30.5b)
Interest Expense / Debt = 4.74% (Interest Expense 785.0m / Debt 16.6b)
Taxrate = 15.53% (253.0m / 1.63b)
NOPAT = 2.01b (EBIT 2.38b * (1 - 15.53%))
Current Ratio = 0.83 (Total Current Assets 6.45b / Total Current Liabilities 7.78b)
Debt / Equity = 2.49 (Debt 16.6b / totalStockholderEquity, last quarter 6.66b)
Debt / EBITDA = 3.93 (Net Debt 14.1b / EBITDA 3.60b)
Debt / FCF = 6.80 (Net Debt 14.1b / FCF TTM 2.08b)
Total Stockholder Equity = 6.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 1.39b / Total Assets 30.5b)
RoE = 21.82% (Net Income TTM 1.39b / Total Stockholder Equity 6.39b)
RoCE = 11.22% (EBIT 2.38b / Capital Employed (Equity 6.39b + L.T.Debt 14.8b))
RoIC = 8.71% (NOPAT 2.01b / Invested Capital 23.1b)
WACC = 6.52% (E(44.3b)/V(60.9b) * Re(7.46%) + D(16.6b)/V(60.9b) * Rd(4.74%) * (1-Tc(0.16)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.21 | Cagr: -4.29%
[DCF] Terminal Value 73.10% ; FCFF base≈2.30b ; Y1≈2.02b ; Y5≈1.63b
[DCF] Fair Price = 73.16 (EV 26.2b - Net Debt 14.1b = Equity 12.1b / Shares 164.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.54 | EPS CAGR: 7.00% | SUE: 0.40 | # QB: 0
Revenue Correlation: 96.96 | Revenue CAGR: 5.37% | SUE: 1.94 | # QB: 4
EPS current Quarter (2027-03-31): EPS=3.15 | Chg30d=-1.06% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=12.96 | Chg30d=-0.05% | Revisions=+35% | GrowthEPS=+8.7% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=14.20 | Chg30d=-1.85% | Revisions=-57% | GrowthEPS=+9.6% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -16% (up=14, down=20)